Ludwig Institute for Cancer Research Limited

Beijing University of Technology

Abbott Laboratories Corporation

Memorial Sloan Kettering Cancer Center

Olivia Newton-john Cancer Research Institute

Dana-farber-cancer Institute Inc.

Andrew Mark Scott

Terrance Grant Johns

Lloyd J Old

Gerd J Ritter

Christopher Robert Bebbington

Elisabeth Stockert

Geoffrey T Yarranton

K Dane Wittrup

Con Panousis

Antony Wilks Burgess

Webster K Cavenee

Edouard Collins Nice

Timothy Edward Adams

Christoph Renner

Achim Jungbluth

Anne Murray

George Mark

Dimitar B Nikolov

Martin Lackmann

Nayanendu Saha

Peter W Janes

Peter Anthony Hoyne

Ermanno Gherardi

Lakmali Atapattu Mudiyanselage

Ginger Chao

Peter Collins

Huei-Jen Su Huang

Anthony Wilks Burgess

Terrance Grant Jonhs

Huei-Jen Huang

Llyod J Old

Elizabeth Stockert

Elisabeth (deceased) Stockert

Expression of proteolytically active, high molecular weight ADAM10 protease is relatively increased in tumour cells that also express the putative tumour stem cell marker CD133. A recombinant humanized antibody or antibody fragment based on 8C7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight ADAM10 protease to thereby detect tumour cells and also as a therapeutic agent for treating cancers, tumours and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumour, renal tumour, prostate cancer, sarcoma and/or melanoma.

Anti-metalloprotease antibody for diagnosis and treatment of cancers

The present invention relates to antibodies that specifically bind to unprocessed c-Met present on the surface of tumor cells. These antibodies are useful in the diagnosis and treatment of cancer or as agents for delivering moieties to cancer cells. The antibodies of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents.

Antibodies directed to the receptor tyrosine kinase c-Met

The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.

Specific binding proteins and uses thereof

Growing community of inventors

Kew East Victoria, Australia

Andrew Mark Scott